When was Nanopath founded?

Nanopath was founded in 2019 and raised its 1st funding round 3 years after it was founded.

Where is Nanopath located?

Nanopath is headquartered in Cambridge, United States.

Who is the current CEO of Nanopath?

Amogha Tadimety of Nanopath. They have also founded 1 company.

How many employees does Nanopath have?

As of Aug 31, 2026, the latest employee count at Nanopath is 29.

Is Nanopath a funded company?

Nanopath is a funded company, having raised a total of $10M across 7 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Jan 01, 2022.

When was the latest funding round of Nanopath?

Nanopath's latest funding was a $***** Grant (prize money) round on May 07, 2025, with participation from 1 investor. Its primary sector is Healthcare IT. In United States, the Healthcare IT sector has seen $6.13B in funding in 2026 to date.

Where does Nanopath rank among its competitors?

Nanopath ranks 2nd amongst 27 active competitors, of which 5 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was Biomarx, which secured $942K in Jan, 2026.

Who are the top competitors of Nanopath?

Nanopath's top competitors include Atrys, Range Bio and OrigiMed. Among them, Biomarx secured the most recent funding round in January, 2026.

Nanopath - 2026 Company Profile, Team, Funding & Competitors

Company Details

Provider of point-of-care molecuolar diagnostic platform for womens health. It offers nanotechnology and assay development platform for the diagnostic paradigm that improves patient outcomes with a focus on pelvic and gynecologic infections.

Website: nanopath.com
Social

Key Metrics

Founded Year

2019

Location

Cambridge, United States

Stage

Series A

Total Funding

$10M in 7 rounds

Latest Funding Round

Grant (prize money), May 07, 2025, $*****

Investors

Medtech Convergence Fund & 8 more

Ranked

2^nd among 27 active competitors

Employee Count

29 as on Aug 31, 2026

Similar Companies

Atrys & 29 more

View Nanopath's full profile

Nanopath has raised a total funding of $10M over 7 rounds. Its first funding round was on Jan 01, 2022. Its latest funding round was a Grant (prize money) round on May 07, 2025 for $*****. 1 investor participated in its latest round. Nanopath has 9 institutional investors.

Here is the list of recent funding rounds of Nanopath:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 07, 2025	1740460	Grant (prize money)	4684308	8118252	2127088	9331993
Feb 21, 2025	8389884	Grant (prize money)	8745713	4441247	3117932	HHS
Jan 24, 2025	1455771	Conventional Debt	9919251	2430328	2661627	6653220

Access funding benchmarks and valuations. Sign up today!

View details of Nanopath's funding rounds and investors

The founders of Nanopath is Amogha Tadimety. Amogha Tadimety is the CEO of Nanopath.

Here are the details of Nanopath's key team members:

Amogha Tadimety: Co-Founder & Co-CEO of Nanopath and founder of 1 other company.
Contact Info: 2 email addresses

View details of Nanopath's Founder profiles and Board Members

Nanopath's employee count trend

Nanopath has 29 employees as of Aug 26. Here is Nanopath's employee count trend over the years:

Uncover Nanopath's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Nanopath include Atrys, Range Bio and OrigiMed. Here is the list of Top 10 competitors of Nanopath, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Atrys 2007, Barcelona (Spain), Public	Provider of diagnostic and therapeutic services catering to cancer	-	ING, Deutsche Bank & 4 others	64/100
2nd	Nanopath 2019, Cambridge (United States), Series A	Provider of point-of-care molecuolar diagnostic platform for womens health	$10M	Norwest, GingerBread Capital & 7 others	43/100
3rd	Range Bio 2022, San Carlos (United States), Seed	Provider of solutions for health monitoring based on translational proteomics	$5.2M	Artis Ventures, Four Cities Capital & 5 others	42/100
4th	OrigiMed 2016, Shanghai (China), Series B	Genetics-based personalized cancer counseling	$10M	Grand Flight Investment, IDG Capital & 4 others	39/100
5th	N-of-One 2008, Lexington (United States), Acqui-Hired	NGS analysis, interpretation, and reporting solutions for research and clinical applications	$17.7M	Allumia Ventures, Philips Ventures & 3 others	39/100
6th	Coral Genomics 2018, San Francisco (United States), Seed	Provider of genomic data based drug development	$150K	Y Combinator, Hemisphere Ventures & 3 others	33/100
7th	NomosLogic 2026, Salt Lake City (United States), Unfunded	Developer of infrastructure for deterministic molecular medicine and genomic analysis	-	-	30/100
8th	Biomarx 2025, Belfast (United Kingdom), Seed	Developer of automated diagnostic systems for molecular testing at point of care	$942K	SFC Capital, Clarendon Fund Managers & 3 others	30/100
9th	BLINK 2015, Jena (Germany), Unfunded	Provider of point-of-care diagnostics tests	-	-	29/100
10th	AureumDx 2021, Glasgow (United Kingdom), Unfunded	Developer of electrochemical biosensing technology for redefining diagnostics	-	-	29/100